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Abstract
Clinical and pathological changes in familial Creutzfeldt-Jakob disease (CJD) cases may be similar or indistinguishable from
sporadic CJD. Therefore determination of novel mutations in PRNP remains of major importance. We identified two
different rare mutations in codon 188 of the prion protein gene (PRNP) in four patients suffering from a disease clinically
very similar to the major subtype of sporadic CJD. Both mutations result in an exchange of the amino acid residue threonine
for a highly basic residue, either arginine (T188R) or lysine (T188K). The T188R mutation was found in one patient and the
T188K mutation in three patients. The prevalence of mutations at codon 188 of PRNP was tested in 593 sporadic CJD cases
and 735 healthy individuals. Neither mutation was found. The data presented here argue in favor of T188K being a
pathogenic mutation causing genetic CJD. Since one individual with this mutation, who is the father of a clinically affected
patient with T188K mutation, is now 79 years old and shows no signs of disease, this mutation is likely associated with a
penetrance under 100%. Further observations will have to show whether T188R is a pathogenic mutation.
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Introduction
Human prion diseases can be idiopathic, acquired or genetic.
The majority of cases are idiopathic and are generally referred to
as sporadic Creutzfeldt-Jakob disease (sCJD). About 10%–15% of
human prion diseases are inherited in an autosomal, dominant
fashion and in all cases a mutation in the coding region of the
human prion protein gene (PRNP) has been found [1,2].
Depending on their clinical and pathological phenotypes, the
inherited prion diseases have been termed as genetic (familial)
CJD, Gerstmann-Stra ¨ussler-Scheinker syndrome (GSS) or fatal
familial insomnia (FFI). More than 20 different point mutations
are known to date which are found to be associated or genetically
linked with inherited prion diseases. These point mutations cluster
in the central and in the more C-terminal part of the prion protein
(PrP) encoded by PRNP.
The most common mutations in inherited human prion diseases
are well described and their phenotypic range has been
determined. The glutamate to lysine mutation at codon 200
(E200K) is causative of the majority of familial CJD cases, the
proline to leucine mutation at codon 102 (P102L) for GSS and the
aspartate to asparagine mutation at codon 178 (D178N) coupled
with methionine at codon 129 for FFI [3–7]. Whereas the clinical
and histopathological spectrum of GSS and FFI differ from sCJD,
the spectrum of familial CJD overlaps in many cases with the
spectrum of sCJD [4] . In the absence of genetic testing of
suspected sCJD, mutations of PRNP often would not be detected
and familial CJD would be underreported. The determination of
novel mutations in PRNP remains of major importance for the
following reasons. (1) The identification of new mutations might
identify some dementing or neurodegenerative clinical syndromes
as prion diseases, thus expanding the spectrum of prion diseases
and improving the differential diagnosis during lifetime. (2) Every
novel mutation adds valuable insights to our understanding as to
how such changes in PrP cause prion diseases. (3) Several
mutations giving rise to a phenotype mimicking sCJD may have
been overlooked due to an examination bias towards known
mutations. This may lead to erroneous diagnoses with implications
for the affected families.
Here we report two different rare mutations at codon 188 of
PRNP in four cases of clinically diagnosed and one autopsy
proven CJD case and argue that mutations at this position are
causative of genetic CJD. The mutations are located in a highly
conserved region and alter the codon 188 from threonine (T) to a
basic amino acid residue, either arginine (T188R) or lysine
(T188K).
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Clinical history/Neuropathology
Patients A–D were identified as part of the German CJD
surveillance program, where about 2000 patients were investigated
clinically, genetically and many of them neuropathologically [5,8].
Patients A–C were not autopsied. For patient D informed consent
for autopsy was received from parents. The relatives of patient D
(sister (E), father (F), mother (G)) were clinically inconspicuous and
received predictive genetic analysis after signed informed consent.
One year before the death of patient D we received a 3-mm
tissue sample from a brain biopsy, after her death a brain autopsy
was performed. The left hemisphere was fixed in formalin and the
right hemisphere was frozen (280uC). Histological examination
was performed on 4 mm thick sections of 17 regions of formalin-
fixed and paraffin embedded cerebrum, cerebellum and brain-
stem. Hematoxylin and eosin (H&E) as well as Gallyas silver stain,
Luxol fast blue–periodic acid Schiff (LFB-PAS) and Bielschowsky
stains were performed using standard techniques. Immunohisto-
chemistry was performed with antibodies directed against PrP
(L42, 1:100, gift from M. Groschup), phosphorylated tau (AT8,
1:200, Innogenetics, Ghent, Belgium), a-synuclein (15G7, 1:10,
own production, [9]) and aB-crystalline (1:500, Calbiochem,
Nottingham, UK). Paraffin-embedded tissue (PET) blotting was
performed using the antibody 12F10 (gift from J. Grassi) as
described elsewhere [10].
Genetic analysis
For genetic analysis DNA was extracted from blood lymphocytes
or from frozen post-mortem brain tissue according to standard
procedures. The coding region of PRNP was amplified by the
polymerase chain reaction (PCR) and first subjected to single-
stranded conformational polymorphism (SSCP) analysis. In case a
mutation was indicated, the complete open reading frame of PRNP
was analyzed by direct sequencing of PCR products using the
automated LICOR 4200 DNA analyzer as described previously [5].
The mutation in patient A was detected by the procedure as
described. The mutations in patients B–D and persons E–G were
detected by direct sequencing without prior SSCP analysis. In
patient C a silent mutation at codon 117 complicated the analysis
due to a polymorphism co-migrating in the region of the 59-primer
leading to preferential amplification of the allele with the silent
mutation [11]. The re-analysis of the coding region of PRNP by
PCR was then performed with a different 59-primer [5].
The amino acid at codon 129 in coupling with the mutation was
determined by cloning. For this purpose, the PCR product was
cleaved with EcoRI (part of primer B [12]) and XmaI (at codon 40
of the prion protein), the large fragment was purified and cloned
into the appropriate cleavage sites of pBluescriptIIKS(-) (Strata-
gene, La Jolla, CA). The mutation and the respective codon 129
were verified by sequencing of three independent clones.
Single nucleotide polymorphism (SNP) analysis
The prevalence of mutations at codon 188 of PRNP was tested
in a sCJD cohort (593 sCJD cases; 387 ‘‘definite’’ and 206
‘‘probable’’ sCJD), received from a large German study on the
genetics of prion diseases, and 735 healthy individuals [13]. The
latter were taken from a population-based German study
performed in the city and region of Augsburg (KORA;
Kooperative Gesundheitsforschung im Raum Augsburg, Survey
4, 2000), which is a representative sample of the adult general
population of German nationality and were matched for age and
gender [14,15]. All study participants gave informed written
consent according to the Bavarian Ethics committee and the
Ethics committee of the Ludwig-Maximilians-University of
Munich.
Genomic DNA of sCJD patients was extracted from blood
lymphocytes according to standard procedures. The SNP analysis
for both mutations (T188R, T188K) was performed using matrix
assisted laser desorption/ionisation time of flight mass spectrom-
etry (MALDI-TOF MS, Mass Array
TM, Sequenom, San Diego,
CA, USA). Briefly, genomic DNA of each subject was tested
individually using PCR with primers 39-ACGTTGGATGT-
CATCTTAACGTCGGTCTCG-59 and 39-ACGTTGGATG-
CACGACTGCGTCAATATCAC-59 generating products of
108 bp. Following purification of the PCR products homogenous
MassEXTEND reactions (hME
TM, Sequenom, San Diego, CA,
USA) were performed by adding a mixture of dideoxy and
deoxynucleotides and the test-specific MassEXTEND primer 39-
TTGGTGGTTGTGGTGACC-59, which is complementary to
the template at a region directly adjacent to the polymorphic site.
The hME products were spotted onto a 384 SpectroCHIP
microarray for fully automated mass spectrometry analysis (Biflex
mass spectrometer, Bruker Daltonik GmbH, Bremen, Germany;
MassArray
TM, Sequenom, San Diego, CA, USA).
Western Blot
For Western blot analysis tissue from the frontal cortex of
patient D was homogenised in 9 volumes (wt/vol) of lysis buffer
(0.5% Nonidet P-40, 0.5% DOC, 10 mM EDTA, 100 mM NaCl,
100 mM Tris, pH 6.9 at 37uC). After PK digestion (100 mg/ml, 1h
at 37uC) cleared homogenates were subjected to SDS-PAGE (12%
NuPage, Invitrogen, Karlsruhe, Germany) and blotted on PVDF-
membranes [16]. For comparison we used brain homogenates
from two sCJD cases (MM1 and VV2). The monoclonal anti-PrP
antibody 3F4 (1:3000, DAKO), recognizing the epitope 109–112
of PrP, was used for immunodetection. Protease-resistant PrP was
visualized by enhanced chemiluminescence reaction (GE Health-
care, Freiburg, Germany).
Results
Clinical history
Patient A. The patient was of Caucasian descent, born and
raised in Germany. She spent the last 33 years of her life in
Indonesia. At age 66 she presented with progressive visual
impairment followed several months later by progressive
dementia and slight ataxia. Her medical history was
unremarkable aside from a malaria episode. On examination
during a visit in Germany, 12 months after onset of the disease,
the patient was oriented towards her person, but disoriented in
time. She had impaired short-term memory and reported
increased exhaustion, tiredness and weight loss. Examination of
her CSF revealed neuron-specific enolase (NSE) of 38 ng/ml (cut-
off 35 ng/ml for an optimum sensitivity and specificity for the
diagnosis of CJD [17]), intrathecal IgG-production and 14-3-3
proteins. In the cerebral magnetic resonance imaging (MRI)
12 months after onset only one small (7 mm) lesion was found in
the frontal white matter on both sides. They were hyperintense on
T2, invisible on T1, non-enhancing and interpreted as
‘‘myelinoclastic lesions’’. The electroencephalogram (EEG)
showed typical periodic sharp-wave complexes (PSWCs). The
sensory evoked potentials (SEP) and acoustical evoked potentials
(AEP) were normal, the monocular visual evoked potentials (VEP)
indicated a demyelinating lesion on both sides, most likely
localized in the prechiasmatic optic nerves. The patient died
16 months after the onset of her disease. An autopsy was not
performed. A family history of dementing illnesses was not known.
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age (31 y).
Patient B. The patient was born in Germany and lived there
for her whole life. At age 76 she presented with coordination
problems of the left hand and slight disturbances of her gait.
Involuntary movements, alien limb-sign, focal dystonia, rigor of
upper extremities, apraxia and ataxia were found. In a first Mini
Mental State Examination (MMSE) test three months after the
onset the patient scored normal. The initial diagnosis was
corticobasal degeneration. Only one month later she was
severely demented. She developed visual problems, up-beat
nystagmus and dysarthria. In the CSF the NSE level was 28 ng/
ml (elevated, but below the cut-off of 35 ng/ml for CJD diagnosis)
and the Western blot for 14-3-3 was positive. The initial MRI, two
months after onset, showed moderate atrophy of the fronto-
parietal cortex and little unspecific white matter lesions fronto-
parietal. The MRI one month prior death revealed an abnormal
T2 signal in the basal ganglia on both sides. The single-photon
emission computed tomography (SPECT) revealed a
hypoperfusion of the parietal cortex bilaterally. The EEG
showed PSWCs. The VEP revealed a delay of the P100
component bilaterally. The patient died 5 months after the onset
of the disease and was not autopsied. At that time, the younger
sister (59 y) was healthy. The mother of the patient was reported
having died aged 64 from a rapidly progressing dementia. Yet, the
parents of the patient’s mother died late in life (74 y and 89 y) of
non-dementing disorders. The son of the patient died from an
unknown liver disease at the age of 51 y.
Patient C. The patient was born and lived for her whole life in
Germany within 140 kilometres from patient B. At age 69 she
presented with vertigo, personality changes and visual disturbances
followed soon after by involuntary movements of the left limbs and a
hemiparesis of the left side. Short-term memory was impaired and
myoclonus was present. Signs of ataxia were diagnosed on
neurological examination three months after onset. The cerebral
MRI two and three months after onset showed mild enlargement of
the ventricular spaces and periventricular unspecific white matter
lesions in the centrum semiovale. PSWCs were indicated in the
EEG. The examination of CSF revealed 14-3-3 proteins and a
clearly elevated NSE level of 140 ng/ml (cut-off 35 ng/ml for CJD
diagnosis). The patient’s condition deteriorated rapidly and she was
bed-ridden with akinetic mutism four months after the onset of the
disease. Three months later, the patient died and no autopsy was
performed. No family history of a dementing disease was known,
both her parents died of unrelated diseases aged 77 and 87 years.
Patient D. The patient lived for her whole life in Germany
within 130 kilometres from patient B and 10 kilometres from patient
C. One year preceding her death this 58 year old woman subacutely
developed dizziness,aphasia,alexia, apraxiaand dysdiadochokinesia
of the right hand. The symptoms were clearly progressive during the
next two weeks. The MRI, one month after onset, showed cortical
signal enhancement of the left temporal lobe. The EEG showed no
regular activity with intermittent bilateral PSWCs. Elevated tau
protein (2218 pg/ml) and 14-3-3 proteins were detectable in the
CSF. According to the criteria for clinical diagnosis of CJD the
diagnosis of ‘‘probable CJD’’ was made [18]. During the following
weeks the disease progressed to a condition of mutism, the muscle
tone increased and myoclonic jerks appeared. She died one year
after the onset of clinical signs in a nursing home. No similar diseases
were reported in her family.
Genetics
Patient A. The analysis of the coding region of PRNP
showed an abnormal pattern in the SSCP analysis compared to
the normal PRNP of patients without sequence aberrations and
to PRNP of patients with various known mutations. Sequencing
revealed a cytosine to guanine transversion at the second
position at codon 188 on one allele resulting in an amino acid
exchange of threonine (ACG) to arginine (AGG) (T188R)
(Figure 1B). The amino acid at codon 129 was valine (V) at
both alleles.
Patients B,C,D and persons E,F,G. Samples of patients
B,C,D and persons E,F,G were directly sequenced after PCR
amplification. A transversion to adenine at the second position at
codon 188 on one allele was observed in persons B–F (Figure 1C).
The resulting amino acid exchange was threonine to lysine (AAG)
(T188K). The mutation in patient C was clearly visible only after
re-analysis with a different PCR-primer due to a polymorphism in
the primer-binding region of the gene that is co-migrating with the
silent mutation at codon 117. In fact, the patient C turned out to
be heterozygous at three positions in the coding region of PRNP:
the silent polymorphism at codon 117 and the codons 129 and
188. As the persons B, C, D, E were heterozygous (methionine
(M)/V) at the polymorphic codon 129, the amino acid at this
position in coupling with lysine at 188 was determined as M in all
cases by molecular cloning. Person F was homozygous at codon
Figure 1. Sequence analysis of PRNP in three patients with prion diseases. The coding region was sequenced using fluorescence-labeled
primers on an automated sequencing system (LI-COR, Lincoln, Neb.). Short fragments of PRNP of (A) a patient with the normal codon 188, (B) patient
A with the T188R mutation and (C) patient B with the T188K mutation are shown using a primer for the sequencing that reads the antisense strand.
doi:10.1371/journal.pone.0002147.g001
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coupled with V at codon 129. The mother of patient D (person G)
did not carry a PRNP mutation.
SNP screening
In order to test the prevalence of the T188R and the T188K
mutations in sporadic CJD and in the healthy population a big study
cohort consisting of 593 sCJD cases and 735 healthy individuals was
screened. The mutations T188R and T188K or different nucleotide
changes at codon 188 were not found in any of the examined
persons.
Histology/Immunohistochemistry (Patient D)
The histological examination of the tissue received from biopsy
showed parts of the neocortex with spongiform changes and gliosis.
Immunohistochemistry with an antibody against the human prion
protein (PrP) (L42) revealed synaptic staining of the cortex.
The neuropathological gross examination of the brain showed a
moderate frontal atrophy, a diminution of cortical thickness in all
regions, enlarged ventricles and a thin corpus callosum. The
cerebellum revealed atrophy, especially of the superior lobe. The
brainstem was macroscopically unaffected. The cerebral vessels
showed mild arteriosclerotic changes. Histological examination of
Figure 2. Post-mortem neuropathological findings in Patient D. A: Spongiform changes in the frontal cortex with numerous ballooned
neurons (H&E, original magnification 1006); Inserts: Immunohistochemistry of ballooned neurons (aB-Crystalline; 206 and 2006). B: Status
spongiosus in the occipital cortex (H&E, 1006). C: Cerebellar cortex with moderate spongiform changes of the molecular layer and severe
degeneration of the granular cell layer (H&E, 206). D–F: Immunohistochemistry with an antibody against PrP (L42) shows a synaptic pattern of PrP
Sc
deposition. D: Frontal cortex (406), E: Retina (4006). F: Cerebellar cortex (206).
doi:10.1371/journal.pone.0002147.g002
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layers of the cerebral cortex, astrocytic gliosis and neuronal
depletion increasing from the frontal (Figure 2A) to the occipital
lobe. Status spongiosus was found in the entorhinal, transentorh-
inal and occipital cortex (Figure 2B), putamen and caudate
nucleus. The globus pallidus and cornu Ammonis showed only
minor spongiform changes, which was more pronounced in the
subiculum and amygdala. The medial and lateral part of the
thalamus showed severe spongiform changes, astrocytic gliosis and
neuronal loss. The nucleus basalis of Meynert revealed moderate
gliosis. Furthermore numerous aB-crystalline immunoreactive
ballooned neurons were found in the cortex of the cingulate
gyrus, the frontal (Figure 2A insert) and temporal lobe and a small
number in the external layer of entorhinal cortex. Mild
demyelination and axonal loss were found mainly in the occipital
lobe. The cerebellar cortex showed moderate spongiform changes
of the molecular layer, severe degeneration of the granular cell
layer with some torpedoes (Figure 2C). The Purkinje cells were
mainly preserved. Moderate atrophy of cerebellar white matter
was noted. The brainstem was nearly free of spongiform change,
but astrocytic gliosis was found mainly in pons and the tegmentum
of the whole brainstem. Immunohistochemistry with an antibody
against the human prion protein (PrP) (L42) revealed strong
synaptic staining of all layers of the cerebral and cerebellar cortex
(Figure 2D,F), the hippocampus, the amygdala, the basal ganglia,
the thalamus, the dentate nucleus, grey matter of the brainstem
and the plexiform layers of the retina (Figure 2E). The PET blot of
the hippocampus and cerebellar cortex showed intensive synaptic
staining. The immunostaining with an antibody against hyperpho-
sphorylated tau protein (AT8) revealed a few neurofibrillary
tangles and neuropil threads in the transentorhinal cortex, the
external and internal layer of the entorhinal cortex and few in the
CA1 region and amygdala. These were not detectable using the
Gallyas silver stain.
Western blot analysis (Patient D)
The protease resistant PrP in brain homogenate from patient D
was further analysed using Western blotting with the antibody 3F4.
AP r P
Sc patterntype 1 wasfound(Figure 3,lane3)similartothetype
1 pattern of sCJD case (MM1, Figure 3, lane 1). In addition there
was a fragment migrating at about 17 kDa detected with the
antibody 3F4. Additional bands have been reported in genetic prion
diseases (mainly GSS), some also in sCJD and iCJD [19–22].
Discussion
Here we present four patients carrying two different mutations
at codon 188 of PRNP - T188K and T188R (for a summary of
findings see Table 1). We show immunohistochemical data
confirming that the T188K mutation is associated with a human
prion disease (CJD) in one case. Patients B, C and D are from the
same circumscribed region in Germany and were born not more
than 140 km from each other; no familial relationship is known.
Persons E and F, the sister and father of Patient D, have a T188K
mutation and are healthy at ages 51 and 79 years respectively.
The case with the T188R (Patient A) mutation is the only one
reported to date [5,23]. A T188K mutation of PRNP was
published in an Austrian patient with rapid progressive dementia
[24]. There is no histological description of these two cases. A
T188A mutation was described in an Australian patient [25].
A comparison of the four cases with the T188K mutation
(patients B–D of this study and the Austrian patient) shows a
heterogeneous clinical picture concerning age at onset (57–76 y),
disease duration (5–13 m), symptoms at onset (ataxia, personality
change and aphasia) and MRI findings (Table1).
The cases B, C and D were originally classified as ‘‘probable
sCJD’’ according to the diagnostic criteria for sCJD established by
the WHO-guidelines as they showed the obligatory criteria and two
(patient B) or all four (patients C and D) of the following clinical
features: myoclonus, visual or cerebellar disturbances, pyramidal or
extrapyramidaldisturbances orakinetic mutism(Table1) [18,26].In
patient D a diagnosis of ‘‘definite CJD’’ was made after death. The
genetic analysis revealed a mutation at codon 188 of PRNP (T188K)
and heterozygosity at codon 129 of PRNP in the three cases. In
patient D the PrP
Sc type 1 was found in the Western blot analysis
(Parchi et al.1999) and the histological picture was indistinguishable
from sCJD-MM1/MV1 [27], except for the numerous ballooned
neurons in the cortex, which are not seen in sCJD-MM1.
A number of PRNP mutations are associated with characteristic
cerebral MRI findings. A signal hyperintensity in the cerebral
cortex more than in the basal ganglia (BG) was recognized as a
characteristic feature in genetic CJD with the PRNP codon V180I
mutation [28]. Mutations in codon 183 and 210 show abnormal-
ities in the BG and cerebral cortex similar to sCJD [29]. Recent
studies revealed that particular sCJD subtypes (MV2, VV1) also
show specific characteristics on MRI [30,31]. In the three cases
with the T188K mutation no characteristic cerebral MRI pattern
was identified. The typical T2 signal in the BG as proposed for
sCJD criteria was found in patient B only [32]. In addition a
hypoperfusion of the parietal cortex bilaterally was found in
SPECT, but not on T2 weighted MRI 2–4 months after onset.
The MRI findings in patient C were uncharacteristic. The isolated
cortical hyperintensity on MRI and the missing BG sign in patient
D may be due to the early time point when the single MRI was
performed (one month after onset) [26,33,34].
Absence of a positive family history is noted in a significant
proportion of genetic CJD cases (5–88%, depending on the
mutation) and has drawn the attention to the issue of penetrance of
mutations [4,12]. Our findings suggest that the T188K mutation
may not be fully penetrant as controversially discussed for other
mutations (E200K, V210I) causing clinical phenotypes very similar
to sCJD or that the pathogenic effect depends on additional factors
Figure 3. Western blot analysis of PrP after proteinase K
digestion (lanes 1–3) using mAb 3F4. Lane1: PrP
Sc type 1 from a
sporadic CJD case. Lane 2: PrP
Sc type 2 from a sporadic CJD case. Lane 3:
Frontal cortex of patient D. As seen in lane 3 there is an additional band
migrating at an apparent MW of 17 kDa.
doi:10.1371/journal.pone.0002147.g003
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whether this is of any significance in Person F, who is clinically not
affected at age 79 and homozygous for M, is unknown at present.
The novel mutation at codon 188 in patient A (T188R) was
found by routine sequencing of CJD suspects in the German
surveillance [5,23]. However, due to the negative family history
and the absence of a genetic analysis of family members there is
no evidence for the disease-causing effect of this mutation. No
autopsy was performed. During clinical examinations CJD was
strongly suspected because of the CJD-specific findings in EEG
and CSF. The pathological VEP is common in CJD, even in
patients without clinically affected visual system [39]. The MRI
pattern was not typical as proposed for the CJD criteria because
of the missing hyperintensity of the BG, even 12 months after
onset, similar to three of four T188K mutations. Clinically
patient A is similar to sporadic MM1/MV1 cases, because of the
drastic visual problems. However, the disease duration (16 m.)
exceeds the mean duration for this group (4–5 months).
Homozygosity for V at codon 129 in this patient is remarkable
since visual symptoms are very unusual in (sporadic) VV1 and
VV2 patients. Dementia and ataxia in the course of the disease
are common, ataxia is more typical of VV2. The PSWCs in
EEG and the age at onset are similar to the sporadic VV2
subgroup, whereas the disease duration is at the outer limit for
VV2.
Similar to all novel point mutations whose causative nature is
not supported by a genetic linkage study, the question arises
whether mutation T188K is truly pathogenic and not merely a
polymorphism accidentally occurring in cases of sCJD. However,
there are several arguments strongly supporting the pathogenic
role of this mutation: (1) It was not identified in 735 healthy
controls. (2) Threonine at codon 188 of PRNP is highly conserved
throughout all mammalians, indicating that this mutation is likely
to have a dramatic effect on the function of the prion protein
[40,41]. Codon 188 is situated in the C-terminal half of the second
alpha-helix, a firmly structured part of the protein, and a drastic
exchange like the substitution of threonine for a highly basic
amino acid such as arginine (T188R) or lysine (T188K) would
Table 1. Features of the prion diseases associated with mutations at codon 188. Abbreviations: AA=amino acid; n.a.=not
available, IHC=Immunohistochemistry; m.=month; M=methionine; V=valine; y.=years.
Patient A Patient B Patient C
Patient D
(Patient)
Person E (Sister
of D)
Person F
(Father of D)
Patient – Austria
[24]
Patient –
Australia [25]
Mutation T188R T188K T188K T188K T188K T188K T188K T188A
Polymorphism at
Codon 129/ AA on
mutated allele
VV V MV M MV M MV M MV M MM M n.a. MM M
Further
polymorphism
A117A_129V
Family history for
neuro -
degenerative
diseases
negative positive negative negative negative negative negative negative
S e x F FF FF M n . a . F
Age at onset (y.) 66 76 69 57 Healthy (at age
51 y.)
Healthy (at age
79 y.)
59 82
Duration of disease
(m.)
16 5 7 13 not applicable not applicable (,1y.) 4
Progressive
dementia
++ ++ ++
Myoclonus - ++ + +
Visual or cerebellar
disturbance
++ ++ +
Pyram./extra-
pyram. dysfunction
- ++ + +
Akinetic mutism - - ++ -
Symptoms at onsetvisual impairment ataxia visual impairment,
personality changes
aphasia, apraxia memory deficits
Cerebral MRI
two unspecific
symmetrical lesions
in the frontal white
matter
atrophy of the
fronto-parietal
cortex, little
unspecific white
matter lesions
fronto-parietal,
abnormal T2
signal in the
basal ganglia.
mild enlargement
of the ventricular
spaces,
periventricular
unspecific white
matter lesions in
the centrum
semiovale (T2)
cortical signal
enhancing and
diffusion
abnormalities
but no
enhancing of
basal ganglia
n.a.
minor cortical
atrophy
PSWCs in EEG ++ ++ n.a. +
14-3-3 ++ ++ n.a. +
Clinical diagnose
according to [18]
criteria for CJD not
fulfilled
Probable CJD probable CJD probable CJD asymptomatic asymptomatic n.a. Probable CJD
Neuropathology n.a. n.a. n.a. CJD n.a. n.a. n.a.
CJD IHC
negative
doi:10.1371/journal.pone.0002147.t001
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PLoS ONE | www.plosone.org 6 May 2008 | Volume 3 | Issue 5 | e2147result in a structural destabilization. (3) Cell culture experiments
are strongly suggestive of a pathogenic role for this mutation, since
increased proteinase K (PK) resistance and insolubility in non-
denaturing detergents have been observed [42].
The data presented here argue in favor of T188K being a
pathogenic mutation causing genetic CJD. Since one individual
with this mutation is now 79 years old and shows no signs of
disease, this mutation may be associated with a penetrance under
100%. Further observations will have to show whether T188R is a
pathogenic mutation.
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